PROCEPT BioRobotics Targets Positive Adjusted EBITDA in Q4 2026
Photo: TokenPost
PROCEPT BioRobotics is targeting positive adjusted EBITDA in Q4 2026, alongside a 2026 revenue outlook of $390 million to $410 million. The company’s full-year adjusted EBITDA outlook is a loss of $30 million to $35 million. The positive target applies to the fourth quarter, while the loss range covers the year. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
